James Bylund sold $331k of RGEN
Chief Operating Officer at REPLIGEN CORP. 2,191 shares at an average of $151.21, traded Nov 18, 2025, filed Nov 19, 2025.
Score components
- +20RoleCOO
- +15Trade size$331k at market
- 0Share of holdings soldSold 9.2% of holdings
- +15Cluster3 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-288160, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 18, 2025 | SOpen-market sale Common Stock | -2,191 | $151.21 | $331k | 21,520 | Nov 19, 2025 |
Related signals
Other insiders at REPLIGEN CORP and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 20Weak | REPLIGEN CORP | Olivier Loeillot Chief Executive Officer | $1.0M 5,535 shares | -12% | |
| 20Weak | REPLIGEN CORP | Olivier Loeillot Chief Executive Officer | $2.5M 12,946 shares | -23% | |
| 20Weak | REPLIGEN CORP | Olivier Loeillot Chief Executive Officer | $977k 5,426 shares | -10% | |
| 23Weak | REPLIGEN CORP | Olivier Loeillot Chief Executive Officer | $504k 3,035 shares | -6% | |
| 21Weak | RGENsell REPLIGEN CORP | Karen A Dawes director | $44k 275 shares | -0% | |
| 50Moderate | REPLIGEN CORP | Olivier Loeillot Chief Executive Officer | $1.2M 7,041 shares | -16% | |
| 45Moderate | REPLIGEN CORP | Anthony Hunt director | $3.1M 20,000 shares | -20% | |
| 25Weak | REPLIGEN CORP | Anthony Hunt director | $3.9M 25,000 shares | -20% | |
| 30Weak | RGENsell REPLIGEN CORP | Anthony Hunt director | $3.5M 29,111 shares | -22% | |
| 53Moderate | RGENbuy REPLIGEN CORP | Martin D Madaus director | $202k 1,800 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.